Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2020 Jun 5:2020.06.04.135046.
doi: 10.1101/2020.06.04.135046.

An OpenData portal to share COVID-19 drug repurposing data in real time

Kyle R Brimacombe  1 , Tongan Zhao  1 , Richard T Eastman  1 , Xin Hu  1 , Ke Wang  1 , Mark Backus  1 , Bolormaa Baljinnyam  1 , Catherine Z Chen  1 , Lu Chen  1 , Tara Eicher  1 , Marc Ferrer  1 , Ying Fu  1 , Kirill Gorshkov  1 , Hui Guo  1 , Quinlin M Hanson  1 , Zina Itkin  1 , Stephen C Kales  1 , Carleen Klumpp-Thomas  1 , Emily M Lee  1 , Sam Michael  1 , Tim Mierzwa  1 , Andrew Patt  1 , Manisha Pradhan  1 , Alex Renn  1 , Paul Shinn  1 , Jonathan H Shrimp  1 , Amit Viraktamath  1 , Kelli M Wilson  1 , Miao Xu  1 , Alexey V Zakharov  1 , Wei Zhu  1 , Wei Zheng  1 , Anton Simeonov  1 , Ewy A Mathé  1 , Donald C Lo  1 , Matthew D Hall  1 , Min Shen  1
Affiliations

An OpenData portal to share COVID-19 drug repurposing data in real time

Kyle R Brimacombe et al. bioRxiv. .

Abstract

The National Center for Advancing Translational Sciences (NCATS) has developed an online open science data portal for its COVID-19 drug repurposing campaign - named OpenData - with the goal of making data across a range of SARS-CoV-2 related assays available in real-time. The assays developed cover a wide spectrum of the SARS-CoV-2 life cycle, including both viral and human (host) targets. In total, over 10,000 compounds are being tested in full concentration-response ranges from across multiple annotated small molecule libraries, including approved drug, repurposing candidates and experimental therapeutics designed to modulate a wide range of cellular targets. The goal is to support research scientists, clinical investigators and public health officials through open data sharing and analysis tools to expedite the development of SARS-CoV-2 interventions, and to prioritize promising compounds and repurposed drugs for further development in treating COVID-19.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. OpenData portal objective.
The goal of the OpenData portal is to provide actionable data and validated methodologies to the global research community to support rapid development of therapeutics against SARS-CoV-2.
Figure 2.
Figure 2.. NCATS SARS-CoV-2 assays currently employed to address a range of both viral and host targets.
Overview of established assays and those in development. These include assays for specific viral targets, viral-host interaction assays, viral detection assays and viral cytopathic effect and replication assays, among others.
Figure 3.
Figure 3.. Representative screen captures from the OpenData portal.
A) OpenData portal home page with updates section. B) OpenData browser tab, with columns depicting activity across various protein-based, biochemical, and cell-based assays via heatmap visualization of compound activity to permit direct comparison across a panel of assays. The browser has both sort and search functionalities to facilitate interrogation of data. C) The portal assay page organizes access to all validated assays and those in development, including methodology, detection strategy and status. D) Detailed assay protocols are provided to allow independent evaluation and confirmation of method and compound activities.
See this image and copyright information in PMC

References

    1. Eastman RT et al. (2020). Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19. ACS Central Science. 6.5 (2020): 672–683. Web. - PMC - PubMed
    1. Ellinger B et al. (2020). Identification of inhibitors of SARS-CoV-2 in-vitro cellular toxicity in human (Caco-2) cells using a large scale drug repurposing collection. Research Square. 10.21203/rs.3.rs-23951/v1 - DOI
    1. Fan H et al. (2020). Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model. Chin Med J. 10.1097/CM9.0000000000000797 - DOI - PMC - PubMed
    1. Gordon DE et al. (2020). A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 10.1038/s41586-020-2286-9 - DOI - PMC - PubMed
    1. Jeon S et al. (2020). Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. Antimicrob Agents Chemother. 10.1128/AAC.00819-20 - DOI - PMC - PubMed

Publication types